The purpose of this study is to compare the standard-of-care chemo-immunotherapy (carboplatin/paclitaxel followed by adriamycin/cyclophosphamide plus pembrolizumab, given in 6 months) treatment for early-stage, triple-negative breast cancer to a shorter non-anthracycline chemo-immunotherapy treatment (carboplatin docetaxel pembrolizumab, given in 4.5 months) that uses fewer drugs and a shorter course of treatment. Researchers aim to determine whether the shorter chemoimmunotherapy without anthracycline chemotherapy is as effective as the standard-of-care anthracycline chemoimmunotherapy treatment for early-stage, triple-negative breast cancer. The study will evaluate how well each treatment works to prevent cancer from returning. Researchers also want to learn whether the shorter chemo-immunotherapy improves patients’ quality of life and causes fewer side effects than the usual treatment. All chemotherapy and immunotherapy drugs used in this study are commonly used to treat triple-negative breast cancer. Participants will be assigned to one of two groups. Group 1 will receive the usual chemo-immunotherapy for triple-negative breast cancer. Group 2 will receive the study treatment using chemo-immunotherapy that is shorter and uses fewer drugs. After chemo-immunotherapy treatment, participants will undergo surgery.
What is the full name of this clinical trial?
S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer , A Randomized Phase III Study
David Chan, Dorothy Park, Jin Sun Bitar, Maryliza El-Masry, Monica Mita, Philomena McAndrew, Swati Sikaria